Vancomycin (hydrochloride)

Vancomycin (hydrochloride)

• CAS Number: 1404-93-9
• UNSPSC Description: Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.
• Target Antigen: Antibiotic; Autophagy; Bacterial
• Type: Natural Products
• Related Pathways: Anti-infection;Autophagy
• Applications: COVID-19-immunoregulation
• Field of Research: Infection; Cancer
• Assay Protocol: https://www.medchemexpress.com/Vancomycin-hydrochloride.html
• Solubility: DMSO : 24 mg/mL (ultrasonic;warming)|H2O : 33.33 mg/mL (ultrasonic)
• Smiles: ClC1=CC([C@H]([C@@H](NC([C@H](NC)CC(C)C)=O)C(N[C@@H](CC(N)=O)C(N[C@@]2([H])C(N[C@]3([H])C4=CC(C5=C(C=C(O)C=C5O)[C@](C(O)=O)([H])NC([C@](NC3=O)([H])[C@H](O)C6=CC=C7C(Cl)=C6)=O)=C(O)C=C4)=O)=O)=O)O)=CC=C1OC8=C(C(O7)=CC2=C8)O[C@H]9[C@@H]([C@H]([C@H](O)[C@@H](CO)O9)O)O[C@@]%10([H])C[C@](N)([C@H](O)[C@H](C)O%10)C.Cl
• Molecular Weight: 1485.71
• References & Citations: [1]Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.|[2]Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.|[3]Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96.Chem Eng J. 2024 Apr 15, 486 150125.|Front Aging Neurosci. 2022 Jul 28;14:858130.|NPJ Biofilms Microbiomes. 2024 Oct 28;10(1):111.|Pol J Microbiol. 2023 Jun 14;72(2):199-208.|Redox Biol. 2023 Oct 10, 102929.|Small. 2021 Dec 19;e2107137.|ACS Infect Dis. 2021 Aug 4.|ACS Infect Dis. 2023 Nov 28.|ACS Infect Dis. 2024 Apr 12;10(4):1327-1338.|ACS Infect Dis. 2024 Jul 27.|ACS Omega. 2023 Feb 2; 8 (6), 5415-5425.|ACS Omega. 2023 Mar 6.|ACS Omega. March 3, 2022.|Adv Funct Mater. 2024 Jun 19.|Am J Chin Med. 2024 Aug 21:1-28.|Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702.|Aquaculture. 2021, 736248.|Biochem Pharmacol. 2024 Oct 23:116593.|bioRxiv. 2024 May 10.|Cancer Immunol Res. 2022 Dec 2;10(12):1542-1558.|Cell Death Dis. 2021 Jun 7;12(6):582.|Cell Metab. 2023 Sep 29:S1550-4131(23)00340-6.|Cell Metab. 2024 Sep 28:S1550-4131(24)00366-8.|Chemosphere. 2019 Jun;225:378-387. |Curr Microbiol. 2023 May 31;80(7):230.|Emerg Microbes Infect. 2022 Feb 22;1-34.|Emerg Microbes Infect. 2024 Dec;13(1):2321981.|Environ Health Perspect. 2022 Jun;130(6):67009.|Front Microbiol. 2020 Jul 31;11:1720.|Genome Biol. 2023 Apr 30;24(1):98.|Gut Microbes. 2023 Dec;15(2):2249143.|Heliyon. 2024 Jan 4.|Infect Drug Resist. 2021 Dec 16;14:5449-5456.|Int J Biol Macromol. 2024 Sep 19:135835.|Int J Med Microbiol. 2020 Jan;69(1):120-131.|Int J Med Sci. 2022 Apr 11;19(4):740-752.|iScience. 2023 Mar.|iScience. 2023 Oct 5.|iScience. 5 January 2022, 103731.|J Agric Food Chem. 2024 Apr 10.|J Appl Microbiol. 2024 Jan 4:lxae001.|J Cell Physiol. 2021 Dec 8.|J Pharm Anal. 2023 Jun 16.|Life Sci. 2020 Nov 15;261:118473.|Microb Biotechnol. 2021 Mar 15.|Microbiol Spectr. 2022 Mar 2;e0054121.|Mol Immunol. 2022 Jul 6;149:94-106.|Mol Pharm. 2022 Oct 21.|Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct 1.|Neural Regen Res. 2024 Sep 1;19(9):2081-2088.|Pharmacol Res. 2024 May 21:205:107229.|Res Sq. 2024 Oct 02.|Research Square Preprint. 2020 Jun.|Transl Res. 2022 Sep 5;S1931-5244(22)00198-0.|Virulence. 2024 Dec;15(1):2367659.|Virulence. 2024 Oct 10:2415952.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched